PR in the Philippines

HO CHI MINH CITY, VIETNAM, Apr 14, 2025 - (ACN Newswire via SeaPRwire.com) - analytica Vietnam 2025, the leading international trade fair for laboratory technology, biotechnology, analysis, and diagnostics, successfully concluded its 9th edition, held from 2–4 April 2025 at the Saigon Exhibition and Convention Center (SECC). Organised by MMI Asia Pte Ltd, a wholly owned subsidiary and regional headquarters of Messe München GmbH (MMG), in collaboration with Vietnam Exhibition and Event Services Co., Ltd (VNEES), and supported by the Ministry of Science and Technology of Vietnam, the event surpassed all previous records in attendance and international participation. This milestone reinforces analytica Vietnam’s reputation as Southeast Asia’s premier platform for scientific innovation, cross-border collaboration, and advanced laboratory solutions.The exhibition welcomed 6,657 visitors, including 5,908 unique attendees from 37 countries, reflecting a 23% increase in unique visitors compared to the 2023 edition. This growth highlights the region's increasing demand for cutting-edge laboratory technologies and the growing prominence of the event on the international stage.Impressive Growth and Strong International Participationanalytica Vietnam 2025 experienced exceptional expansion, with a 52% increase in exhibitors. The exhibition hosted over 300 companies and brands across a 7,000 sqm exhibition space, a 56% increase in space compared to 2023. A notable 71% of exhibitors were international, underscoring the event’s rising international appeal and establishing it as a key meeting point for global industry leaders.Prakash Mishra, Head of Vietnam SLS Commercial at Merck Vietnam, remarked, “The quality of visitors this year has been very good—we’ve met professionals from across Asia, Europe, and even the US who are genuinely interested in understanding and entering the Vietnam market. For us, this has been an excellent opportunity to connect with both local and international partners. It’s encouraging to see Vietnam gaining more visibility on the global stage, and analytica Vietnam has played a key role in that. Overall, it’s been a strong start to the year, and we’re leaving the show with meaningful leads and a very positive outlook.”Key Show Features and HighlightsAcademic ConferenceThe concurrent academic conference attracted 770 participants, a notable increase from the 582 attendees in 2023. The conference provided a comprehensive program featuring industry experts and thought leaders, addressing key research trends, technological advancements, and challenges faced by the laboratory and biotechnology sectors.Southeast Asia’s First Live Lab PremiereA key highlight of analytica Vietnam 2025 was the debut of Southeast Asia’s first Live Lab, attracting over 770 participants. This immersive experience offered live demonstrations in a real laboratory environment, allowing attendees to interact with experts and explore the latest technologies in action. It provided valuable, hands-on insights into the practical applications of modern lab workflows.Hosted Buyer Program:analytica Vietnam 2025 welcomed 544 Hosted Buyers from Vietnam and neighboring countries including Laos, Cambodia, Thailand, and Malaysia. With over 700 pre-arranged meetings, the program fostered meaningful business engagement, paving the way for strategic partnerships and regional growth across the laboratory and analytical sectors.Startup PavilionThe Startup Pavilion showcased emerging companies in the laboratory sector, spotlighting innovations and new technologies that are poised to shape the future of the industry. This section of the exhibition offered a platform for fresh ideas and groundbreaking solutions that are advancing laboratory technology.Lab Design and Construction ForumThe Lab Design and Construction Forum delved into the future of sustainable and efficient laboratory infrastructure. The forum featured insights from industry leaders and experts on how modern design principles are transforming laboratory facilities to meet the growing demands of science, research, and industry.Innovation ZoneThe Innovation Zone was a dedicated space showcasing breakthrough technologies that are transforming laboratory operations and industry practices. Attendees had the opportunity to explore cutting-edge products and solutions that are shaping the future of laboratory technology.Exclusive Lab ToursSpecially curated Lab Tours took participants behind the scenes of leading research and testing facilities in Vietnam. These tours offered a deeper understanding of local industry advancements and provided insights into the real-world applications of the technologies showcased at the event.Future Editions: analytica Convention 2026 in Hanoi & analytica Vietnam 2027 in Ho Chi Minh CityBuilding on the remarkable success of analytica Vietnam 2025, MMI Asia is set to extend its reach across Vietnam. The analytica Convention 2026 will take place from April 22–24, 2026, at the International Exhibition Center (ICE) in Hanoi. Designed as an exclusive gathering, this event will feature a top-tier scientific conference and a focused showcase of laboratory technologies, offering industry professionals and academics in Northern Vietnam direct access to global innovations.The full-scale edition of analytica Vietnam will return to Ho Chi Minh City from March 31 to April 2, 2027, at the Saigon Exhibition and Convention Center (SECC). With expectations for greater international presence and broader industry coverage, the 2027 edition will continue to serve as a strategic hub for technology exchange, partnerships, and market expansion in Southeast Asia.About analytica Vietnamanalytica Vietnam is the premier trade fair for laboratory technology, analysis, and biotechnology in Southeast Asia. Organized by Messe München, the event brings together industry professionals, researchers, and policymakers to showcase the latest technologies,exchange knowledge, and foster business collaborations. analytica Vietnam features an exhibition, conference, pre-event laboratory tours, buyer-seller programs, and networking opportunities, providing a comprehensive platform for the laboratory and biotechnology industries in the region. The upcoming edition is set to take place from April 2 to 4, 2025 at the SECC – Saigon Exhibition and Convention Center. More details can be found at https://www.analyticavietnam.com/.About analytica worldwideMesse München is the world’s leading trade fair organizer for laboratory technology, analysis and biotechnology. The international network of exhibitions includes analytica, analytica China, analytica Anacon India & India Lab Expo, analytica Vietnam and analytica Lab Africa. About MMI Asia Pte LtdEstablished in 1992, MMI Asia is the wholly owned subsidiary and the regional headquarters of Messe München GMBH (MMG) and is one of the world largest and leading exhibition organizers. MMI Asia’s portfolio of events include editions of worldleading trade fairs from Munich – transport logistic & air cargo, analytica, ceramitec; as well as industry-specific events such as Glasstech and Fenestration Asia, Asia Climate Forum, and Singapore International Water Week. MMI Asia also provides consultancy in professional trade fair and conference management to government bodies, international trade and promotion organizations, and trade associations. For more information, please visit www.mmiasia.comAbout Messe MünchenAs one of the world’s leading trade fair organizers, Messe München presents the world of tomorrow at its about 90 trade fairs worldwide. These include twelve of the world’s leading trade fairs such as bauma, BAU, IFAT, electronica, and ISPO. Messe München’s portfolio comprises trade fairs for capital and consumer goods, as well as for new technologies. Together with its subsidiaries, it organizes trade fairs in China, India, Brazil, South Africa, Turkey, Singapore, Vietnam, Hong Kong, Thailand, and the U.S. With a network of more than 15 affiliated companies and almost 70 representations worldwide, Messe München is active in more than 130 countries. The more than 150 events held annually attract around 50,000 exhibitors and around three million visitors in Germany and abroad.Exhibition Contact:MMI Asia Pte. Ltd.Daniel ShiExhibition Directordaniel@mmiasia.com.sgPress Contact:MMI Asia Pte. Ltd.Joey NgMarketing Executive joey@mmiasia.com.sg  Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 15, 2025 - (ACN Newswire via SeaPRwire.com) – The latest Standard Chartered GBA Business Confidence Index (GBAI) jointly published by Standard Chartered and the Hong Kong Trade Development Council (HKTDC) today indicated broad-based improvement in business sentiment in the region for the first quarter of 2025.The GBAI “current performance” index for business activity rose to 53.5 in Q1 from 50.7 prior – the highest since Q2-2024. Six of the eight index components rose quarter-on-quarter, and all previous sub-50 underperformers rallied back above the neutral mark, namely “capacity utilisation” (+3.2pts), “raw material inventory” (+9.0pts), “financing scale” (+3.2pts) and “profits” (+3.1pts).The GBAI “expectations” index for business activity improved in tandem with its “current performance” counterpart, to 54.3 in Q1 from 52.9 in Q4-2024. Encouragingly, seven of eight expectation sub-indices rose quarter-on-quarter, led by a 3.1 percentage point increase in “profits” and a 2.8 percentage point increase in “raw material inventory”.All the city sub-indices, be it “current performance” or “expectations”, rose quarter-on-quarter, with Shenzhen being the only exception. Hong Kong extended its rising “current performance” streak to four straight quarters, to 53.5; its “expectations” index jumped to 56.9 – bested only by Guangzhou – from 50.8 prior. Guangzhou’s current and expectation prints stood at 60.3 and 58.0, respectively, the highest among cities.This showed that GBA companies weathered the initial rounds of US tariff hikes (10%+10%) well, in part thanks to the DeepSeek breakthrough lifting market sentiment as well as the rising prospect of more policy stimulus from China’s policymakers. However, respondents’ more-upbeat outlook in February-March (when the Q1 survey was conducted) likely did not prepare them for recent events – US’ announcement of sweeping and sizeable reciprocal tariff hikes on China and most other countries.Kelvin Lau, Senior Economist, Greater China and North Asia, Standard Chartered, said: “Given the urgency to stabilise market sentiment following the tariff-induced sell-off, the likelihood of China cutting the reserve requirement ratio and/or policy rate (7-day reverse repo rate) in April has materially increased. We expect that both monetary and fiscal policies on the Mainland will stay supportive. Meanwhile, Hong Kong would need to ramp up short-term support to SMEs and continue to diversify its trade to facilitate more non-US trade corridors. Our next survey, to be conducted in May-June, should provide a better view of the readiness of GBA businesses to live with high tariffs.”More consumption boosts welcomedLooking ahead, 41% of respondents saw a positive impact from the consumption boosting initiatives announced by China in January. Meanwhile, 38% said the consumer goods trade-in programme would bring positive impact on their business. When asked what else the government could do to expand the consumption-supportive measures, the most popular suggestion was “relax market access for private sector and foreign investment to help boost services consumption”.Wing Chu, Principal Economist (Greater China Research Team), HKTDC, said: “Boosting domestic demand is one of the government’s top priorities, as highlighted in the Government Work Report delivered by Chinese Premier Li Qiang in March. More than 50% of respondents have indicated that they are either already well positioned to tap into the mainland consumer market or are currently expanding or planning to expand their operations to do so. Additional supportive measures from the government could further bolster their businesses.”About the GBAIThe GBAI is the first forward-looking quarterly survey in the market that looks at the business sentiment and synergistic effects in cities and industries across the GBA. It is compiled based on a survey of more than 1,000 companies in the GBA covering the manufacturing and trading, retail and wholesale, financial services, professional services and innovation and technology sectors. The index enables investors and businesses to better understand the current business climate, gauge future performance prospects and formulate their market strategies for the GBA.Related materialsStandard Chartered GBA Business Confidence Index Report: https://www.sc.com/hk/gba/gba-index-report/HKTDC Research: https://research.hktdc.com/en/article/MTk4MDY0MTYwOQ(From left) Kelvin Lau, Senior Economist, Greater China and North Asia, Standard Chartered, and Wing Chu, Principal Economist (Greater China Research Team), HKTDC, announced the latest GBA Business Confidence Index (GBAI) today (15 April 2025). Kelvin Lau, Senior Economist, Greater China and North Asia, Standard Chartered Wing Chu, Principal Economist (Greater China Research Team), HKTDCMedia enquiriesCorporate Affairs DepartmentStandard Chartered Bank (Hong Kong) Limited Flora Chiu Tel: (852) 3843 2285 Email: flora.chiu@sc.com   Communications & Public Affairs DepartmentHKTDC Katy WongClayton Lauw    Tel: (852) 2584 4524Tel: (852) 2584 4472Email: katy.ky.wong@hktdc.orgEmail: clayton.y.lauw@hktdc.orgAbout Standard CharteredWe are a leading international banking group, with a presence in 53 of the world’s most dynamic markets. Our purpose is to drive commerce and prosperity through our unique diversity, and our heritage and values are expressed in our brand promise, here for good.Standard Chartered PLC is listed on the London and Hong Kong stock exchanges.The history of Standard Chartered in Hong Kong dates back to 1859. It is currently one of the Hong Kong SAR’s three note-issuing banks. Standard Chartered incorporated its Hong Kong business on 1 July 2004, and now operates as a licensed bank in Hong Kong under the name of Standard Chartered Bank (Hong Kong) Limited, a wholly owned subsidiary of Standard Chartered PLC. For more stories and expert opinions please visit Insights at sc.com. Follow Standard Chartered on X, LinkedIn, Instagram and Facebook.About HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 14, 2025 - (ACN Newswire via SeaPRwire.com) - On 10 April, Ausnutria Dairy Corporation Ltd (Stock Code: 1717.HK) released its 2024 annual results announcement. According to the announcement, Ausnutria achieved operating revenue of approximately RMB7.402 billion in 2024, a year-on-year (“YoY”) growth of 0.3% and profit attributable to equity holders of the parent company of approximately RMB236 million, a YoY growth of 35.3%, realizing a resilient dual growth in revenue and profit. It is worth mentioning that Ausnutria's international business has entered the fast lane with a significant YoY growth of 68.2%, which has become a new growth driver.According to the announcement, in 2024, in the face of the internal and external economic situation of the world's economic growth momentum and insufficient effective domestic demand, Ausnutria steadily promoted the “milk powder + nutrition products” nutrition strategy for the whole family and further strengthened its leading position as the “World’s No.1 goat milk powder brand”. Through multi-dimensional measures such as strengthening scientific innovation, expanding market, enhancing efficiency and consolidating foundation, Ausnutria has maintained its market share against the backdrop of the overall shrinking infant formula market, realizing revenue growth with a significant increase in profit, thereby surpassing the industry cycle with resilient growth.  In terms of segmentation, Ausnutria's own brand milk powder business segment achieved an overall revenue of approximately RMB5.806 billion, of which the goat milk powder business realized revenue of approximately RMB3.699 billion, representing a YoY increase of 12.7%, while the cow milk powder business realized revenue of approximately RMB2.107 billion. The nutrition products business segment realized revenue of approximately RMB305 million, representing a YoY increase of 7.1%. In terms of region, in 2024, the goat milk powder business of the PRC recorded revenue of approximately RMB3,053 million, representing a YoY growth of 5.3%, while the goat milk powder international business realized revenue of approximately RMB647 million, representing a significant YoY growth of 68.2%, which maintained a high growth trend. The share of total revenue from the Company's own brand formula goat milk powder business further increased to 17.5%.According to the announcement, the Middle East region has continued to show solid growth momentum in 2024; the CIS market achieved high double-digit growth; and a milestone breakthrough was achieved in the first year of the launch of Kabrita’s goat IMF in the U.S. market. Through the dual-track strategy of “online precise promotion + offline channel expansion”, Kabrita quickly grabbed the top category seller on the Amazon platform and was awarded the “Best Goat Milk Baby Formula Product” in the US. Ausnutria said in the announcement that with more and more medical professionals and professional organizations further recognizing the value of goat milk, North America is expected to become another strategic growth pole after the Middle East. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Apr 15, 2025 - (ACN Newswire via SeaPRwire.com) - HighTide Therapeutics, Inc. (2511.HK), a clinical-stage biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for chronic liver and metabolic diseases, today announced that two Phase 3 trials (SYMPHONY 1 and SYMPHONY 2) of berberine ursodeoxycholate (HTD1801) in Chinese patients with type 2 diabetes mellitus (T2DM) met their primary endpoints and gated secondary endpoints.The results of these two Phase 3 clinical trials provide robust evidence that HTD1801 delivers comprehensive benefits for patients with T2DM. Based on these highly positive read-outs, HighTide plans to submit a new drug application (NDA) for HTD1801 as a treatment for T2DM to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) later this year.SYMPHONY 1 (NCT06350890) and SYMPHONY 2 (NCT06353347) are randomized, double-blind, placebo-controlled, Phase 3 clinical trials designed to evaluate the efficacy and safety of HTD1801 in adults with T2DM and inadequate glycemic control despite using diet and exercise (SYMPHONY 1; N=407) or Metformin (SYMPHONY 2; N=549). The primary endpoint in both studies was the change in HbA1c from baseline with HTD1801 compared to placebo after 24 weeks of treatment. Gated secondary endpoints included the percentage of subjects achieving HbA1c <7.0%, change in fasting plasma glucose (FPG), low-density lipoprotein cholesterol (LDL-C), glutamyl transpeptidase (GGT), and high-sensitivity C-reactive protein (hs-CRP).The primary endpoint was achieved in both trials, showing a clinically meaningful, consistent glucose-lowering effect of HTD1801SYMPHONY 1 (HTD1801 as monotherapy): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.3%) was superior to placebo. Further, those with more severe disease had a greater decrease with HTD1801: reduction in HbA1c was -1.5% for those with a baseline HbA1c ≥8.5%.SYMPHONY 2 (HTD1801 as an add-on therapy to Metformin): At week 24, the reduction from baseline in HbA1c with HTD1801 (-1.2%) was superior to placebo. Further, those with more severe disease had a more significant decrease with HTD1801: reduction in HbA1c was -1.6% for those with a baseline HbA1c ≥8.5%.In both Phase 3 trials, the efficacy on HbA1c reduction in patients treated with HTD1801 was sustained through week 24.In both trials, gated secondary endpoints were achieved, suggesting multiple advantages of HTD1801 beyond glucose-lowering including improvement in cardiometabolic risk indicatorsAt week 24, in both studies, the proportion of patients who achieved HbA1c <7.0% was significantly higher in the HTD1801 treatment groups compared to placebo. Improvements in HbA1c with HTD1801 were parallelled with significant improvements in postprandial and fasting plasma glucose compared with placebo. In addition, HTD1801 demonstrated lipid-lowering effects, including significant reductions in low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C). Moreover, HTD1801 treatment led to reductions in key inflammatory biomarkers - glutamyl transpeptidase (GGT) and high-sensitivity C-reactive protein (hs-CRP) - both of which are associated with cardiovascular risk in patients with T2DM.Favorable safety and tolerability profile Overall, safety and tolerability were favorable and consistent with previous clinical trials of HTD1801. The most commonly reported adverse events were gastrointestinal. In both studies <2% of patients discontinued early due to an adverse event. The incidence of hypoglycemia was low, with no severe hypoglycemia events reported.“The encouraging results from these studies suggest that HTD1801 may offer a novel and improved therapeutic option for patients with T2DM,” said Dr. Linong Ji, the leading principal investigator for the two Phase 3 clinical trials and former Vice President of the International Diabetes Federation (IDF), Director of the Peking University Diabetes Center and Director of the Department of Endocrinology and Metabolism, Peking University People’s Hospital. “As an innovative drug candidate, HTD1801 exhibits a unique dual mechanism of action - AMP kinase activation and NLRP3 inflammasome inhibition - that is distinct from any existing T2DM drugs on the market. It is an oral therapy designed to deliver comprehensive clinical benefits - not only lowering blood glucose but also improving lipid metabolism and exerting anti-inflammatory effects - thereby potentially reducing diabetes-related complications and addressing significant unmet clinical needs. With continued clinical exploration, HTD1801 is expected to further expand its application to benefit patients globally. In today’s pharmaceutical landscape, investment has become heavily concentrated on GLP-1-based drug development. While GLP-1 therapies hold significant clinical value, they do not adequately address the full spectrum of pathophysiological mechanisms underlying T2DM. To truly meet the multifaceted needs of T2DM management, continued innovation across a diverse range of therapeutic targets remains essential.”“We extend our deepest gratitude to the patients who participated in these pivotal trials,” said Dr. Liping Liu, HighTide’s founder and CEO. “HTD1801’s innovative dual-action approach – targeting both metabolic regulation and inhibiting inflammation – represents a potential breakthrough in diabetes treatment. We look forward to sharing data from the 28-week open-label extension of these studies and a Phase 3 head-to-head comparison with the dapagliflozin; we will continue to explore the clinical potential of HTD1801 to provide patients with chronic metabolic diseases a comprehensive treatment solution.”About Type 2 Diabetes Mellitus (T2DM)According to the International Diabetes Federation (IDF), 537 million adults (ages 20-79) were living with diabetes in 2021, and this number is projected to grow to 783 million (representing 1 in 8 adults) by 2045, of these, around 90% are T2DM cases. China has the largest population of diabetes patients worldwide, estimated to be 141 million in 2021, and projected to grow to 174 million in 2045. Diabetes is a global societal burden leading to over 6 million deaths per year. To address this urgent challenge, there is a critical need for innovative therapies that can deliver comprehensive clinical benefits for patients worldwide.About Berberine Ursodeoxycholate (HTD1801)Berberine ursodeoxycholate (HTD1801) is an orally delivered, gut-liver anti-inflammatory metabolic modulator being developed for the treatment of metabolic and digestive diseases. HTD1801, an ionic salt of berberine and ursodeoxycholate, is a new molecular entity with a unique dual mechanism of action: AMP kinase activation and NLRP3 inflammasome inhibition. These two key mechanistic pathways have been associated with improvements in insulin resistance, glucose metabolism, lipid metabolism, and hepatic inflammation, potentially providing a comprehensive treatment platform for the multifaceted nature of complex metabolic diseases.HTD1801 is being developed for multiple indications. In addition to T2DM, its efficacy in treating metabolic dysfunction-associated steatohepatitis (MASH) has been demonstrated in a Phase 2a clinical trial and a global multicenter Phase 2b trial assessing the histologic benefit of HTD1801 is currently ongoing, with topline results expected in 2025.About HighTide TherapeuticsHighTide Therapeutics, Inc. (Stock Code: 2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional, multi-targeted therapies with poly-indication potential across chronic liver and metabolic diseases with significant unmet medical needs. HighTide is currently developing several clinical assets and associated global intellectual property rights, and advancing multiple mid-to-late-stage clinical trials including therapies for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes mellitus (T2DM), severe hypertriglyceridemia (SHTG) and primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), HighTide’s lead drug candidate, received Fast Track designation from the United States Food and Drug Administration for both MASH and PSC and Orphan Drug designation for PSC. HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project in China.For more information, please visit www.hightidetx.com.Contact: pr@hightidetx.com Copyright 2025 ACN Newswire via SeaPRwire.com.